GlassScriptPhysician profile
Shilpi Singh
NPI 1871970160
$3,845.19
in general payments reported to CMS, 2019-2025
37 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $216 · 2021: $469 · 2022: $664 · 2023: $1,019 · 2024: $619 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,023.92 | 2019-2025 | Unithroid |
| Lilly USA, LLC | $318.84 | 2019-2024 | Jardiance, Mounjaro, Baqsimi |
| Novo Nordisk INC | $246.90 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $224.93 | 2019-2024 | Saphnelo |
| Medtronic, INC. | $209.89 | 2021-2025 | Minimed 780g |
| Amgen INC. | $166.10 | 2021-2025 | Prolia, Evenity, Krystexxa |
| Dexcom, INC. | $154.02 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $139.56 | 2019-2023 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $120.79 | 2020-2024 | |
| Medtronic Minimed, INC. | $105.70 | 2019-2020 | |
| Abbott Laboratories | $102.78 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.01 | 2021-2023 | Jardiance |
| Mannkind Corporation | $83.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $76.59 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $70.21 | 2022-2023 | Gvoke Hypopen |
| Abbvie INC. | $65.81 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.50 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $56.10 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $52.77 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $27.87 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $27.80 | 2019 | |
| Corcept Therapeutics | $27.54 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $27.30 | 2023 | Signifor Lar, Isturisa |
| Hikma Pharmaceuticals USA | $26.95 | 2021 | |
| Pfizer INC. | $26.62 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $22.33 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Biotech, INC. | $18.40 | 2023 | Tremfya |
| Depuy Synthes Sales INC. | $18.31 | 2023 | Orthovisc, Monovisc |
| Insulet Corporation | $16.92 | 2023 | Omnipod |
| Ucb, INC. | $16.76 | 2022 | |
| Genentech USA, INC. | $15.88 | 2024 | Actemra |
| Kyowa Kirin, INC. | $15.79 | 2023 | Crysvita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2022 | |
| Sobi, INC | $14.76 | 2022 | |
| Ibsa Pharma INC. | $14.34 | 2023 | Tirosint, Licart |
| Embecta Corp. | $13.79 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpi Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.